Fabulous AI provides an AI‑driven platform that designs fully human monoclonal antibodies in silico within 3–5 days, delivering a curated shortlist of 20 candidates optimized for affinity, thermostability, manufacturability, and minimal off‑target binding. The service leverages a curated human sequence library and iterative germinal‑center‑style maturation to produce antibodies ready for in‑vitro validation and accelerated therapeutic development.
Funding
Funding not disclosed
Founders
Product
Problem
Developing therapeutic monoclonal antibodies traditionally requires extensive laboratory screening and iterative engineering, leading to long timelines, high costs, and uncertainty around human compatibility, thermostability, and off‑target effects.
Solution
Fabulous AI offers an AI‑driven platform that designs fully human monoclonal antibodies entirely in silico within 3–5 days. By starting from curated human sequence databases and applying an iterative maturation process that mimics natural germinal‑center evolution, the service generates a premium shortlist of 20 candidates optimized for high affinity, superior thermostability, manufacturing readiness, and minimal off‑target binding. The platform tailors designs to the specific target, intellectual‑property landscape, and downstream development requirements, delivering candidates that are ready for in‑vitro validation and accelerated clinical progression.
Target Audience
Primary customers are biotech and pharmaceutical R&D teams seeking fast, high‑confidence human antibody candidates for therapeutic development, as well as academic labs requiring custom antibodies for research.
Features
- AI‑augmented pipeline that selects and refines antibodies from a curated human sequence library
- In silico maturation that emulates germinal‑center evolution to improve efficacy and reduce adverse‑reaction risk
- Rapid turnaround of 3–5 days from target definition to a validated shortlist of 20 fully human antibodies
- Designs optimized for high affinity, low cross‑reactivity, superior thermostability, and manufacturing yield
- Compatibility with diverse targets including viral proteins, cancer biomarkers, immunology markers, and membrane proteins
- Delivered sequences include IP‑freedom analysis and manufacturing‑readiness assessment